A 15-year-old female received an unrelated three of six HLA antigen matched umbilical cord blood (UCB) transplant for refractory, relapsed T-cell ALL. Conditioning consisted of TBI, melphalan, and anti-thymocyte globulin (ATG), with cyclosporin A (CsA) and solumedrol for GVHD prophylaxis. She engrafted and a day 34 bone marrow aspirate showed 100% donor cells and no evidence of leukemia. The post-transplant course was complicated by mild grade I acute GVHD involving skin, and limited chronic GVHD of the gut which resolved with the addition of 1 mg/kg/day of steroids to her CsA prophylaxis. One hundred and ninety days after transplantation the patient developed pancytopenia and was subsequently found to have a leukemic relapse. Immunosuppression was discontinued and she was started on G-CSF and erythropoietin. Moderate skin and gut GVHD developed which was treated with both topical and low-dose oral steroids. Over the next few weeks she became transfusion independent and a follow-up bone marrow aspirate showed complete remission. She continued in complete remission for 4 months, at which time localized leukemic relapse was found in a soft tissue breast mass in spite of continued bone marrow remission. from BMT but lack a suitably matched conventional transplant donor.
from BMT but lack a suitably matched conventional transplant donor. [1] [2] [3] [4] Preliminary results have suggested that UCB transplantation may be associated with a lower incidence of acute GVHD than unrelated bone marrow, and require less stringent HLA matching. [2] [3] [4] While less GVHD is a potential benefit of UCB transplantation, there is concern that UCB may not be able to generate a sufficient GVL effect in patients with hematologic malignancies, resulting in increased relapse rates and limiting its practical utility. In this report we describe a patient who relapsed after undergoing UCB transplantation from a partially mismatched (3/6) unrelated donor for refractory relapsed T cell ALL. A complete remission was achieved following discontinuation of immunosuppression and institution of cytokine support. Whether UCB cells generate a GVL effect in all patients is unknown, but this case report clearly demonstrates that UCB has the potential to generate a GVL effect and this effect can be powerful enough to induce a complete remission. As the biology and mechanisms of GVHD and GVL are more completely understood, it may become possible to uncouple these two immune responses and maximize the benefits of hematopoietic stem cell transplantation without compromising anti-leukemic effects.
Case report
A 15-year-old white female had been diagnosed with CD7 + ALL at 12 years of age after presenting with fever and a sore throat. Her peripheral blood smear showed a white blood cell count of 2600/l with 38% blasts. On immunophenotyping, the blasts were positive for expression of CD7, HLA DR, and CD34. Cytogenetics revealed an abnormal karyotype with partial deletions of chromosomes 16 and 20, and trisomy of chromosomes 21 and 22. The CSF was negative at diagnosis and she achieved a CR on day 35 following induction with daunomycin, cyclophosphamide, vincristine, prednisone, l-asparaginase, and intrathecal cytarabine (per Childrens Cancer Group (CCG) protocol 1901). Consolidation therapy with cyclophosphamide, 6-mercaptopurine, cytarabine, vincristine, l-asparaginase and 1800 cGy of prophylactic cranial radiation was followed by two cycles of interim maintenance therapy along with (Table  1) . Conditioning therapy consisted of fractionated TBI (1350 cGy in nine fractions given twice daily from day −9 to day −5) followed by melphalan 45 mg/m 2 once daily i.v. for 3 days (from day −4 to day −2), and ATG 30 mg/kg once daily i.v. for 3 days (from day −3 to day −1). GVHD prophylaxis consisted of CsA (goal trough 150-250 ng/ml) and solumedrol (1 mg/kg/day from day 0 to day +4, 2 mg/kg/day from day +5 to day +21; then gradually weaned). She engrafted with an ANC greater then 500/l on day 28 post transplant. A day 34 bone marrow aspirate showed no evidence of leukemia, with chimerism studies demonstrating 100% donor cells ( Figure 1 ). The patient achieved red cell transfusion independence on day 106 post transplant, but failed to achieve platelet transfusion independence secondary to leukemic relapse. The post-transplant course was complicated by grade I acute GVHD involving skin only, which resolved with topical steroids. She had a second GVHD flare of the gut on day 140 post transplant treated with 1 mg/kg/day of steroids in addition to her prophylactic CsA. Six days later, she had a CsAinduced seizure and was switched to FK506 (goal trough 5-10 ng/ml). On day 198 she developed pancytopenia and was shown to be in isolated bone marrow relapse with cellular areas of the bone marrow being occupied almost entirely by lymphoblasts. Morphologically the blasts looked similar to her original leukemia. Immunophenotyp- ing was notable for continued expression of CD34 with loss of the CD7 expression that had been present at initial diagnosis. FK506 was discontinued, steroids were weaned to physiologic replacement doses (5 mg prednisone daily), and she was started on daily G-CSF and three times weekly erythropoietin. She subsequently developed grade II skin and gut GVHD treated with topical steroids, and doubling her oral steroids. Over the next few weeks she became transfusion independent. Repeat peripheral blood chimerism studies on day 245 showed no evidence of host cells and a follow-up bone marrow aspirate showed complete remission with 100% donor cells. Four months later the patient was noted to have a soft tissue breast mass which proved to be a local recurrence of her leukemia on biopsy. Host origin of the leukemia was confirmed by HLA typing. A bone marrow aspirate was obtained which showed no evidence of leukemia and chimerism studies of both peripheral blood and bone marrow continued to show 100% donor cells. The patient was given palliative local radiation therapy to the breast mass and sent home with hospice care. Over the next several weeks her counts began to slowly decline and she subsequently died 3 months later of presumed progressive disease.
Discussion
GVHD occurring after bone marrow transplantation has been closely linked to the GVL response in multiple studies. [5] [6] [7] [8] The importance of T cells in generating both the GVHD and GVL immune response has been shown experimentally and validated by clinical trials comparing T cell depleted with unmanipulated bone marrow transplantation. [9] [10] [11] As expected, T cell-depleted marrow generates less GVHD, but is also associated with a higher risk of relapse, which is felt to be due to a loss of the GVL response. The diminished GVHD observed by some investigators following UCB transplantation, raises the concern that cord blood-derived cells may not be capable of generating a sufficient GVL response. The case described in this report illustrates that UCB cells, in conjunction with cytokine support, can generate a GVL response in a recipient of a mismatched, unrelated UCB transplant. Furthermore, this case shows that the GVL response generated by cord blood can be powerful enough to induce a complete remission.
Several authors have described GVL-induced complete remissions following allogeneic bone marrow transplan-tation for both acute and chronic leukemia. [12] [13] [14] While discontinuation of immunosuppression may be sufficient to induce a complete remission in some cases, the use of donor lymphocyte infusions has proved to be a more powerful means of generating a GVL response. 15, 16 Donor lymphocyte infusions have clearly been shown to benefit patients with relapsed CML for whom a complete morphologic response rate of greater than 70% has been reported. 15, 16 Complete responses have also been reported in patients with relapsed AML and ALL, although the frequency is much less than that seen in CML, and fewer of these responses result in durable complete remissions. 16 One shortcoming of banked unrelated UCB transplantation is that there is no continuing source of donor cells for additional therapy. Therefore, while discontinuing immunosuppression may induce a GVL response, the much more powerful tool of donor lymphocyte infusions is unavailable. Although traditional donor lymphocytes are not a therapeutic option after banked UCB transplantation, the fact that UCB is capable of generating a GVL response opens up the possibility that novel methods could be developed to augment this response and optimize the GVL effect generated following UCB transplantation.
In order to develop rational approaches for optimizing the GVL response following UCB transplantation, it will be important to investigate exactly which cells contribute to the GVL response. While the importance of T cells has been demonstrated, in vitro and in vivo studies have also shown that natural killer (NK) and lymphokine-activated killer (LAK) cells contribute to the GVL immune response independent of the T cell-mediated GVHD/GVL response. 17, 18 In addition, studies in patients with CML have demonstrated that circulating CD8
+ and NK cells were significantly lower in patients who relapsed compared to those who remained in remission, and that the GVL effect was independent of CD4 + cell counts and the grade of clinical GVHD. 19 The importance of NK and LAK cells in generating a GVL response is further supported by clinical studies which demonstrate a rise in these cell types associated with a GVL effect following allogeneic BMT and donor lymphocyte infusions, but not following high-dose chemotherapy. 20, 21 Interestingly, these cell types have also been shown to rise following autologous transplantation, which suggests that the immune dysregulation following ablative therapy may contribute to this pattern of cellular activation. 20 Although cord blood has been shown to contain a higher number of NK cells then adult peripheral blood, 22 the in vitro cytotoxicity of fresh UCB-NK cells is significantly lower than that of adult peripheral blood cells as measured by 51 Cr release and MTT assays. Following a brief incubation with IL-2, UCB cytotoxicity is greatly increased to levels comparable with adult blood cells. 17, 23 IL-2 has previously been used in vivo to augment the GVL effect following both autologous and allogeneic BMT for a variety of both leukemic and non-leukemic malignancies. 24 In a study by Soiffer et al, 25 low-dose continuous IL-2 infusion was given to patients following T cell-depleted allogeneic bone marrow transplantation for hematologic malignancies. Patients were eligible once they had achieved stable engraftment without evidence of GVHD greater than grade Bone Marrow Transplantation I. The drug was well tolerated, with only four of 29 patients withdrawn from the study early, and only one patient developing acute GVHD. Results of this study suggest that the risk of relapse and overall disease-free survival were superior in the IL-2-treated group compared with historical controls. IL-2 may therefore be a reasonable candidate for trials attempting to augment the GVL effect following UCB transplantation.
Another possible approach could take advantage of evidence from the recent clinical trials showing that UCB may be safely expanded ex vivo. 26 The identification of specific cell populations responsible for the generation of GVL, combined with ex vivo cell expansion technology, opens up the possibility for studies directed towards selective expansion of the cells responsible for the GVL response. A third possible approach could be to utilize dendritic cell vaccines to enhance or induce an immune response against the patient's malignant cells. While the methods for augmenting the GVL response after UCB transplantation remain to be determined, the demonstration that UCB is capable of generating a GVL effect makes the pursuit of such methods a viable option for future study.
